Medicxi Ventures Management (Jersey) Ltd - Oct 28, 2021 Form 3 Insider Report for Aura Biosciences, Inc. (AURA)

Role: 10%+ Owner
Signature: Medicxi Ventures Management (Jersey) Limited, By: /s/ Giles Johnstone-Scott, Its: Director
Stock symbol: AURA
Transactions as of: Oct 28, 2021
Transactions value $: $0
Form type: 3
Date filed: 10/28/2021, 08:20 PM
Previous filing: Jun 4, 2021
Next filing: Nov 4, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AURA	Series D-1 Convertible Preferred Stock							Oct 28, 2021	Common Stock	1.65M		See footnote	F1, F2, F5
holding	AURA	Series D-2 Convertible Preferred Stock							Oct 28, 2021	Common Stock	374K		See footnote	F1, F3, F5
holding	AURA	Series E Convertible Preferred Stock							Oct 28, 2021	Common Stock	252K		See footnote	F1, F4, F5
holding	AURA	Series D-1 Convertible Preferred Stock							Oct 28, 2021	Common Stock	39.2K		See footnote	F1, F2, F6
holding	AURA	Series D-2 Convertible Preferred Stock							Oct 28, 2021	Common Stock	8.88K		See footnote	F1, F3, F6
holding	AURA	Series E Convertible Preferred Stock							Oct 28, 2021	Common Stock	5.98K		See footnote	F1, F4, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Immediately prior to the completion of the Issuer's initial public offering ("IPO"), each share of Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock, on a 13.7-for one basis and has no expiration date.
F2	Upon the closing of the Issuer's IPO, all shares of the Series D-1 Convertible Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3.
F3	Upon the closing of the Issuer's IPO, all shares of the Series D-2 Convertible Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3.
F4	Upon the closing of the Issuer's IPO, all shares of the Series E Convertible Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3.
F5	Held by Medicxi Growth I LP, a Jersey limited partnership ("Medicxi Growth I"). Medicxi Growth I GP Limited, a Jersey limited liability company ("MGI GP"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company ("Medicxi Manager") is the sole manager of Medicxi Growth I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose.
F6	Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership ("Medicxi Growth Co-Invest I"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose.